Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...

Members of the International Hearing Society (IHS) are gearing up to celebrate World Hearing Day on March 3, 2025, to raise awareness of hearing healthcare and address the stigma attached to hearing ...

CoinW, a global leader in cryptocurrency exchanges, made a strong impression at Consensus HK 2025 as an official 4 Block ...

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

There are plenty of great investment alternatives in the healthcare sector. You won't need a boatload of money to get started ...

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare ...

Vertex reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Trikafta/Kaftrio drive year-over-year sales.

AbbVie, Danaher, Organovo, Thermo Fisher Scientific, and Vertex Pharmaceuticals are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of ...

Strong demand for its CF therapy, Trikafta/Kaftrio, delivered $10.2 billion in revenue for the year. We appreciate that Vertex is using its healthy cash flows from its CF franchise to expand its ...

An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, ...

This can be attributed to: Vertex Pharmaceuticals’ revenue growth has been driven by strong uptake in Trikafta/Kaftrio – a prescription medicine used for the treatment of cystic fibrosis ...